This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the recent data presented from Exact Science and Natera at ASCO GI on the Oncodetect and Signatera MRD tests for Colorectal Cancer Detection

Ticker(s): EXAS, NTRA

Who's the expert?

Institution: Cancer Care Centers of South Texas

  • Hematologist/Oncologist at Cancer Care Centers of South Texas 
  • Manages 20+ patients with Colorectal Cancer
  • Specializing in the management of all adult solid tumors, lymphomas and leukemias and regularly orders Minimal Residual Disease testing 

Interview Questions
Q1.

Roughly how many patients do you see per month for colorectal cancer?

Added By: ben_admin
Q2.

Have you ordered any Measurable residual disease (MRD) tests? If so, which?

Added By: ben_admin
Q3.

What are the differences between the current MRD tests on the market?

Added By: ben_admin
Q4.

What is your opinion on the MRD tests from Exact Sciences and Natera?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.